Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
ArQule |
---|---|
Information provided by: | ArQule |
ClinicalTrials.gov Identifier: | NCT00302172 |
To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.
Condition | Intervention | Phase |
---|---|---|
Cancer Tumor |
Drug: ARQ 197 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients With Metastatic Solid Tumors |
Estimated Enrollment: | 78 |
Study Start Date: | January 2006 |
Arms | Assigned Interventions |
---|---|
ARQ 197: Experimental |
Drug: ARQ 197
Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days). Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks. All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted. |
To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197 given orally. This is an open label, dose escalation study of ARQ 197 administered orally at a starting dose of 10 mg bid (20 mg/day).
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Premiere Oncology | |
Santa Monica, California, United States, 90404 | |
United States, Ohio | |
The Cleveland Clinic | |
Cleveland, Ohio, United States, 44195 | |
United States, Texas | |
Mary Crowley Medical Research Center | |
Dallas, Texas, United States, 75246 |
Responsible Party: | ArQule, Inc. ( ArQule ) |
Study ID Numbers: | ARQ 197-101 |
Study First Received: | March 10, 2006 |
Last Updated: | August 25, 2009 |
ClinicalTrials.gov Identifier: | NCT00302172 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Cancer solid tumor metastatic primary tumor |